Document:

mrtemploymentagreement

                         EMPLOYMENT AGREEMENT          This Employment Agreement (this “Agreement”) is made and entered into by and between   Flotek Industries, Inc., a Delaware corporation (the “Company”), and Matthew R. Thomas   (“Employee”) effective as of May 18, 2020 (the “Effective Date”).          1.    Employment.  During the Employment Period (as defined in Section 4), the   Company or one of its subsidiaries shall employ Employee, and Employee shall serve, as President   of JP3 Measurement, LLC (“JP3”) and as Executive Vice President of the Company’s Analysis &   Data Division and in such other position or positions as may be assigned from time to time by the   Company.          2.    Duties and Responsibilities of Employee.                (a)   During the Employment Period, Employee shall report to the Chief   Executive Officer of the Company and shall devote Employee’s best efforts and full business time   and attention (except for permitted paid time off in accordance with Section 6(b) and periods of   illness in accordance with the applicable Company policies) to the businesses of the Company and   its direct and indirect subsidiaries as may exist from time to time (collectively, the   “Company Group”) as may be requested by the Company from time to time.  Employee’s duties   and responsibilities shall include those normally incidental to the position(s) identified in Section   1, as well as such additional duties as may be assigned to Employee by the Company from time to   time, which duties and responsibilities may include providing services to other members of the   Company Group in addition to the Company.  Employee may, without it being considered a   violation of this Section 2(a): (i)  as a passive investment, own publicly traded securities in such   form or manner as will not require any services by Employee in the operation of the entities in   which such securities are owned; (ii) engage in charitable, professional, trade association,   community, religious, and civic activities; (iii) attend to Employee’s personal matters and finances;   or (iv) with the prior written consent of the board of directors of the Company (the “Board”),   engage in other personal and passive investment activities or serve on a board, in each case, so  long as such ownership, interests or activities do not interfere with Employee’s ability to fulfill   Employee’s duties and responsibilities under this Agreement and are not inconsistent with   Employee’s obligations to any member of the Company Group or competitive with the business   of any member of the Company Group.  Employee’s principal place of employment shall be JP3’s   Austin, Texas office, subject to reasonable business travel from time to time.                (b)   Employee hereby represents and warrants that Employee is not the subject   of, or a party to, any employment, non-competition, non-solicitation, restrictive covenant or non-  disclosure agreement, or any other agreement, obligation, restriction or understanding that would   prohibit Employee from executing this Agreement or fully performing each of Employee’s duties   and responsibilities hereunder, or would in any manner, directly or indirectly, limit or affect any   of the duties and responsibilities that may now or in the future be assigned to Employee hereunder.    Employee expressly acknowledges and agrees that Employee is strictly prohibited from using or   disclosing any confidential information belonging to any prior employer in the course of   performing services for any member of the Company Group, and Employee promises that   Employee shall not do so.  Employee shall not introduce documents or other materials containing      

 

 confidential information of any prior employer to the premises or property (including computers  and computer systems) of any member of the Company Group.                (c)   Employee owes each member of the Company Group such fiduciary duties   that an officer of the Company has under the laws of the State of Delaware, and the obligations   described in this Agreement are in addition to, and not in lieu of, the obligations Employee owes   each member of the Company Group under statutory and common law.          3.    Compensation.                (a)   Base Salary.  During the Employment Period, the Company shall pay to   Employee an annualized base salary of $337,500, which shall automatically be increased to   $375,000 on January 1, 2021, in consideration for Employee’s services under this Agreement,   payable in substantially equal installments in conformity with the Company’s customary payroll   practices for similarly situated employees as may exist from time to time, but no less frequently  than monthly.  The amount of the Base Salary may not be decreased without the written consent   of Employee, other than a general reduction in base salaries that affects all similarly situated   executives of the Company in substantially the same proportion; provided, however, such general   reduction may not exceed 20% of Employee’s Base Salary.  The amount of the Base Salary may   be increased as determined in the sole discretion of the Board (or a committee thereof).    Employee’s annualized base salary, as adjusted from time to time, is hereafter referred to as the   “Base Salary.”                (b)   Annual Bonus.  Employee shall be eligible for discretionary cash bonus   compensation with a target amount equal to seventy-five percent (75%) of Employee’s Base Salary  for each complete calendar year that Employee is employed by the Company hereunder (the  “Annual Bonus”).  Notwithstanding the foregoing, Employee shall be eligible to receive a pro   rata portion of the Annual Bonus for the portion of the 2020 calendar year that Employee is  employed by the Company hereunder (the “2020 Bonus”).  The performance targets that must be   achieved in order to be eligible for certain bonus levels shall be established by the Board (or a   committee thereof) annually, in its sole discretion, and communicated to Employee in the   applicable calendar year (the “Bonus Year”) and for the 2020 Bonus, shall be communicated to   the Employee no later than June 30, 2020.  Each Annual Bonus (and the 2020 Bonus), if any, shall   be paid as soon as administratively feasible after the Board (or a committee thereof) certifies   whether the applicable performance targets for the applicable Bonus Year have been achieved.    Notwithstanding anything in this Section 3(b) to the contrary, except as expressly provided in   Section 7(f)(i)(C), no Annual Bonus (or the 2020 Bonus), if any, nor any portion thereof, shall be   payable for any Bonus Year unless Employee remains continuously employed by the Company   from the Effective Date through the date on which such Annual Bonus or the 2020 Bonus is paid.                (c)   Equity Awards.                    (i)     Subject to approval by the Board (or a committee thereof), on the        Effective Date or within thirty (30) days thereafter, Employee shall receive (i) a number of        shares of restricted Company common stock (“RSAs”) calculated by dividing $412,500 by         the average volume weighted average price (“VWAP”) of the Company’s common stock         over the twenty (20) trading days immediately preceding the Effective Date and (ii) stock                                          2 

 

      options to purchase a number of shares of Company common stock (“Options,” with the        RSAs, the “Equity Awards”) calculated by dividing $375,000 by the average VWAP of        the Company’s common stock over the twenty (20) trading days immediately preceding       the Effective Date, with each such Option having an exercise price equal to the closing       price of the Company’s common stock on the Option grant date.  The Equity Awards will       be subject to and governed by the terms and conditions (including vesting conditions)        provided in the applicable award agreements and other governing documents.         Notwithstanding any provision of this Agreement, in no event will the Options be        exercisable prior to the date on which the issuance of the shares of Company common stock       underlying the Options has been approved by the New York Stock Exchange.                  (ii)     For the portion of the Employment Period on or after January 1,        2021, Employee shall be eligible to receive annual awards under the Company’s 2018        Long-Term Incentive Plan or such other equity incentive plan of the Company as may be        in effect from time to time (the “Incentive Plan”).  All awards granted to Employee under        the Incentive Plan, if any, shall be in such amounts and on such terms and conditions as        the Board or a committee thereof shall determine from time to time, and shall be subject to        and governed by the terms and provisions of the Incentive Plan as in effect from time to        time and the award agreements evidencing such awards.  Nothing herein shall be construed        to give Employee any rights to any amount or type of grant or award except as provided in        an award agreement and authorized by the Board or a committee thereof.         4.    Term of Employment.  The initial term of Employee’s employment under this  Agreement shall be for the period beginning on the Effective Date and ending on  December 31, 2021 (the “Initial Term”).  On the first day following the Initial Term and each  subsequent anniversary thereafter, the term of Employee’s employment under this Agreement shall  automatically renew and extend for a period of twelve (12) months (each such twelve (12)-month  period being a “Renewal Term”) unless written notice of non-renewal is delivered by either party  to the other not less than sixty (60) days prior to the expiration of the then-existing Initial Term or  Renewal Term, as applicable.  Notwithstanding any other provision of this Agreement,  Employee’s employment pursuant to this Agreement may be terminated at any time in accordance  with Section 7.  The period from the Effective Date through the expiration of this Agreement or,  if sooner, the date on which Employee’s employment terminates pursuant to this Agreement,  regardless of the time or reason for such termination (the “Termination Date”), shall be referred  to herein as the “Employment Period.”         5.    Business Expenses.  Subject to Section 23, the Company shall reimburse  Employee for Employee’s reasonable out-of-pocket business-related expenses actually incurred  during the Employment Period in the performance of Employee’s duties under this Agreement so  long as Employee timely submits all documentation for such expenses, as required by Company  policy in effect from time to time.  Any such reimbursement of expenses shall be made by the  Company upon or as soon as practicable following receipt of such documentation (but in any event  not later than the close of Employee’s taxable year following the taxable year in which the expense  is incurred by Employee).         6.    Benefits.                                            3 

 

             (a)   During the Employment Period, Employee shall be eligible to participate in   the same benefit plans and programs in which other similarly situated Company employees are  eligible to participate, subject to the terms and conditions of the applicable plans and programs in  effect from time to time.  The Company shall not, however, by reason of this Section 6, be   obligated to institute, maintain, or refrain from changing, amending, or discontinuing, any such   plan or policy, so long as such changes are similarly applicable to similarly situated Company   employees generally.                (b)   During the Employment Period, Employee shall be eligible to take 20 days   of paid time off per year (which will be prorated for 2020, provided that Employee will carry over   Employee’s vacation balance with JP3) in accordance with the Company’s paid time off policy as   in effect from time to time.  Any accrued but unused paid time off entitlement at the end of each   calendar year or the end of the Employment Period will be treated in accordance with the  Company’s paid time off policy as in effect from time to time.          7.    Termination of Employment.                (a)   Company’s Right to Terminate Employee’s Employment for Cause.  The   Company shall have the right to terminate Employee’s employment hereunder at any time for   Cause.  For purposes of this Agreement, “Cause” shall mean:                     (i)     Employee’s material breach of this Agreement or any other written         agreement between Employee and one or more members of the Company Group, including         Employee’s material breach of any representation, warranty or covenant made under any         such agreement;                   (ii)     Employee’s material breach of any policy or code of conduct         established by a member of the Company Group and applicable to Employee;                   (iii)    Employee’s material violation of any law applicable to the        workplace (including any law regarding anti-harassment, anti-discrimination or anti-       retaliation);                   (iv)    Employee’s  gross negligence, willful misconduct, breach of        fiduciary duty, fraud, theft, malfeasance, dishonesty, embezzlement or misappropriation of        the property of any member of the Company Group;                   (v)     the commission by Employee of, or conviction or indictment of        Employee  for, or plea of nolo contendere by Employee to, any felony (or state law        equivalent) or any crime involving moral turpitude; or                   (vi)    Employee’s willful failure or refusal, other than due to Disability (as        defined below), to perform Employee’s obligations pursuant to this Agreement or to follow        any lawful directive from the Company, as determined by the Company;           provided, however, that if Employee’s actions or omissions as set forth in this Section         7(a)(vi) are of such a nature that they are curable by Employee, such actions or omissions                                           4 

 

       must remain uncured thirty (30) days after the Company first provided Employee written         notice of the obligation to cure such actions or omissions.                (b)   Company’s Right to Terminate for Convenience.  The Company shall have   the right to terminate Employee’s employment for convenience at any time and for any reason, or   no reason at all, upon written notice to Employee.                (c)   Employee’s Right to Terminate for Good Reason.  Employee shall have the   right to terminate Employee’s employment with the Company at any time for Good Reason.  For   purposes of this Agreement, “Good Reason” shall mean:                    (i)     a material diminution in Employee’s Base Salary other than a         general reduction in Base Salary that affects all similarly situated executives of the         Company in substantially the same proportion; provided, however, such general reduction         may not exceed 20% of Employee’s Base Salary;                   (ii)     a material diminution in Employee’s authority, duties and         responsibilities with the Company Group; provided, however, that if Employee is serving         as an officer or member of the board of directors (or similar governing body) of any         member of the Company Group or any other entity in which a member of the Company         Group holds an equity interest, in no event shall the removal of Employee as an officer or         board member, regardless of the reason for such removal, constitute Good Reason; or                   (iii)    the relocation of the geographic location of Employee’s principal         place of employment by more than seventy-five (75) miles from the location of Employee’s         principal place of employment as of the Effective Date.    Notwithstanding the foregoing provisions of this Section 7(c) or any other provision of this   Agreement to the contrary, any assertion by Employee of a termination for Good Reason shall not   be effective unless all of the following conditions are satisfied: (A) the condition giving rise to   Employee’s claim of Good Reason must have arisen without Employee’s consent; (B) Employee   must provide written notice to the Board of the existence of such condition(s) within thirty (30)   days after the initial occurrence of such condition(s); (C) the condition(s) specified in such notice   must remain uncorrected for thirty (30) days following the Board’s receipt of such written notice;  and (D) the date of Employee’s termination of employment must occur within thirty (30) days   after the end of the period referenced in clause (C).  Further notwithstanding the foregoing, no   suspension of Employee or reduction in Employee’s authority, duties and responsibilities in   conjunction with any leave required, or other action taken by the Company as part of any   investigation into alleged wrongdoing by Employee shall give rise to Good Reason.                (d)   Death or Disability.  Upon the death or Disability of Employee during the   Employment Period, Employee’s employment with the Company shall automatically (and without   any further action by any person or entity) terminate with no further obligation under this   Agreement of either party hereunder.  For purposes of this Agreement, a “Disability” shall exist   when Employee is unable to perform the essential functions of Employee’s position (after   accounting for reasonable accommodation, if applicable and required by applicable law), due to   physical or mental impairment that continues, or can reasonably be expected to continue, for a                                          5 

 

 period in excess of ninety (90) consecutive days or for a total of one hundred twenty (120) days,   whether or not consecutive (or for any longer period as may be required by applicable law), in any   twelve (12)-month period or, in the event the Company has a long-term disability insurance policy   covering Employee that insures against “permanent disability,” the term “Disability” shall have  the meaning ascribed to such term under such policy.  In the event of a dispute regarding a   “Disability” determination, the Employee will submit to a physical examination by a licensed  physician who is mutually and reasonably agreeable to the Company and Employee.                (e)   Employee’s Right to Terminate for Convenience.  In addition to   Employee’s right to terminate Employee’s employment for Good Reason, Employee shall have   the right to terminate Employee’s employment with the Company for convenience at any time and   for any other reason, or no reason at all, upon sixty (60) days’ advance written notice to the  Company;  provided, however, that if Employee has provided notice to the Company of  Employee’s termination of employment, the Company may determine, in its sole discretion, that  such termination shall be effective on any date prior to the effective date of termination provided  in such notice (and, if such earlier date is so required, then it shall not change the basis for  Employee’s termination of employment nor be construed or interpreted as a termination of  employment pursuant to Section 7(b)).                (f)   Effect of Termination.                    (i)     If Employee’s employment hereunder is terminated prior to the         expiration of the then-existing Initial Term or Renewal Term, as applicable, by the         Company without Cause pursuant to Section 7(b), or is terminated by Employee for Good         Reason pursuant to Section 7(c), then so long as (and only if) Employee: (A) executes on         or before the Release Expiration Date (as defined below), and does not revoke within any         time provided by the Company to do so, a release of all claims in a form reasonably         acceptable to the Company (the “Release”), which Release shall release each member of         the Company Group and their respective affiliates, and the foregoing entities’ respective         shareholders, members, partners, officers, managers, directors, fiduciaries, employees,         representatives, agents and benefit plans (and fiduciaries of such plans) from any and all         claims, including any and all causes of action arising out of Employee’s employment with         the Company and any other member of the Company Group or the termination of such         employment, but excluding all claims to severance payments Employee may have under         this Section 7; and (B) abides by the terms of each of Sections 9, 10 and 11, then the         Company shall provide Employee with the payments and benefits set forth in Sections         7(f)(i)(A), 7(f)(i)(B), 7(f)(i)(C), and 7(f)(i)(D) below (collectively, the “Severance         Benefits”):                             (A)   severance payments to Employee in a total amount equal to               six (6) months’ worth of Employee’s Base Salary for the year in which such               termination occurs (such total severance payments, the “Salary Continuation”),               and such Salary Continuation will be divided into substantially equal installments               paid over the six (6)-month period following Termination Date (the “Severance               Period”), provided that, subject to Section 23(d), on the Company’s first regularly               scheduled pay date that is on or after the date that is sixty (60) days after the               Termination Date (the “First Payment Date”), the Company shall pay to                                          6 

 

 Employee, without interest, a number of such installment payments equal to the   number of such installment payments that would have been paid during the period   beginning on the Termination Date and ending on the First Payment Date had the   installments been paid on the Company’s regularly scheduled pay dates on or   following the Termination Date, and each of the remaining installments shall be   paid on the Company’s regularly scheduled pay dates during the remainder of such   six (6)-month period;                (B)   a payment equal to 50% of the Annual Bonus for the Bonus   Year that includes the Termination Date, with the amount of the Annual Bonus to   be determined by the Board (or a committee thereof) based on actual performance   for the entire Bonus Year that includes the Termination Date, to be paid to   Employee when annual bonuses for the applicable year are paid to similarly situated  executives of the Company, but in no event later than March 15 of the calendar year  following the calendar year in which the Termination Date occurs; and the Board  (or a committee thereof) will evaluate, in its sole discretion, whether and in what   proportion any unvested Equity Awards will become vested;                (C)   any earned but unpaid Annual Bonus for the calendar year   immediately preceding the Termination Date, determined without regard to the   requirement that Employee remain employed through the date of payment, to be   paid to Employee when such bonus would otherwise become payable in accordance   with Section 3(b) hereof, but in no event (x) earlier than 60 days following the   Termination Date or (y) later than March 15 of the calendar year following the   calendar year in which the Termination Date occurs; and any vested Equity Award   that has not yet been settled will be settled as provided in the award agreements and   other governing documents under which the Equity Awards are granted; and                (D)   during the portion, if any, of the Severance Period that   Employee elects to continue coverage for Employee and Employee’s spouse and   eligible dependents, if any, under the Company’s group health plans pursuant to the   Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the   Company shall promptly reimburse Employee on a monthly basis for the difference   between the amount Employee pays to effect and continue such coverage and the   employee contribution amount that similarly situated employees of the Company   pay for the same or similar coverage under such group health plans (the “COBRA   Benefit”).  Each payment of the COBRA Benefit shall be paid to Employee on the   Company’s first regularly scheduled pay date in the calendar month immediately   following the calendar month in which Employee submits to the Company   documentation of the applicable premium payment having been paid by Employee,   which documentation shall be submitted by Employee to the Company within thirty   (30) days following the date on which the applicable premium payment is paid.    Employee shall be eligible to receive such reimbursement payments for coverage   up to the earliest of: (x) the last day of the Severance Period; (y) the date Employee   is no longer eligible to receive COBRA continuation coverage; and (z) the date on   which Employee becomes eligible to receive coverage under a group health plan   sponsored by another employer (and any such eligibility shall be promptly reported                              7 

 

             to the Company by Employee); provided however that the election of COBRA               continuation coverage and the payment of any premiums due with respect to such               COBRA continuation coverage shall remain Employee’s sole responsibility, and               the Company shall not assume any obligation for payment of any such premiums               relating to such COBRA continuation coverage.  Notwithstanding the foregoing, if               the COBRA Benefit cannot be provided in the manner described above without               penalty, tax or other adverse impact on the Company or any other member of the               Company Group, then the Company and Employee shall negotiate in good faith to               determine an alternative manner in which the Company may provide substantially               equivalent benefits to Employee without such adverse impact on the Company or               such other member of the Company Group.                   (ii)     Notwithstanding anything herein to the contrary, the Severance         Benefits (and any portion thereof) shall not be payable if Employee’s employment         hereunder terminates (A) pursuant to any of the circumstances described in Sections 7(a),         7(d), or 7(e) above or (B) upon the expiration of the then-existing Initial Term or Renewal         Term, as applicable, as a result of a non-renewal of the term of Employee’s employment         under this Agreement by the Company or Employee pursuant to Section 4.                   (iii)    If the Release is not executed and returned to the Company on or        before the Release Expiration Date, and any required revocation period has not fully        expired without revocation of the Release by Employee, then Employee shall not be        entitled to any portion of the Severance Benefits.  As used herein, the “Release Expiration         Date” is that date that is twenty-one (21) days following the date upon which the Company         delivers the Release to Employee (which shall occur no later than seven (7) days after the         Termination Date) or, in the event that such termination of employment is “in connection         with an exit incentive or other employment termination program” (as such phrase is defined         in the Age Discrimination in Employment Act of 1967), the date that is forty-five (45) days         following such delivery date.                (g)   After-Acquired Evidence.  Notwithstanding any provision of this   Agreement to the contrary, in the event that the Company determines that Employee is eligible to   receive the Severance Benefits pursuant to Section 7(f) but, after such determination, the Company   subsequently acquires evidence or determines and provides Employee with written notice that: (i)   Employee has failed to abide by the terms of Sections 9, 10 or 11; or (ii) a Cause condition existed   prior to the Termination Date that, had the Company been fully aware of such condition, would   have given the Company the right to terminate Employee’s employment pursuant to Section 7(a),   then the Company shall have the right to cease providing the Severance Benefits and Employee  shall promptly return to the Company all Severance Benefits received by Employee prior to the  date that the Company determines that the conditions of this Section 7(g) have been satisfied;   provided, however, Employee will only be required to return such Severance Benefits if the   Company provides the written notice required under this Section 7(g) no later than the date that is   twelve (12) after the Termination Date.          8.    Disclosures.                                           8 

 

             (a)   Employee hereby represents and warrants that as of the Effective Date there   exist (i) no actual or potential Conflicts of Interest and (ii) no current or pending lawsuits, claims   or arbitrations filed against or involving Employee or any trust or vehicle owned or controlled by   Employee.                (b)   Promptly (and in any event, within seven (7) business days) upon becoming   aware of (i) any actual or potential Conflict of Interest or (ii) any lawsuit, claim or arbitration   involving moral turpitude or that might impair the reputation of Employee and that is filed against  or involving Employee or any trust or vehicle owned or controlled by Employee, in each case,   Employee shall disclose such actual or potential Conflict of Interest or such lawsuit, claim or   arbitration to the Chief Executive Officer or General Counsel of the Company.                (c)   A “Conflict of Interest” shall exist when Employee engages in, or plans to   engage in, any activities, associations, or interests that conflict with Employee’s duties,   responsibilities, authorities, or obligations for and to any member of the Company Group.            9.    Confidentiality.  In the course of Employee’s employment with the Company and   the performance of Employee’s duties hereunder on behalf of any member of the Company Group,  Employee will be provided with, and have access to, Confidential Information (as defined below).   In consideration of Employee’s receipt and access to such Confidential Information, and as a  condition of Employee’s employment hereunder, Employee shall comply with this Section 9.                  (a)   Both during the Employment Period and thereafter, except as expressly  permitted by this Agreement or by directive of the Board, Employee shall not disclose any  Confidential Information to any person or entity and shall not use any Confidential Information  except for the benefit of the Company Group.  Employee shall follow all policies and protocols of   each member of the Company Group regarding the security of all documents and other materials   containing Confidential Information (regardless of the medium on which Confidential Information   is stored).  Except to the extent required for the performance of Employee’s duties on behalf of a   member of the Company Group, Employee shall not remove from facilities of any member of the   Company Group any equipment, drawings, notes, reports, manuals, invention records, computer   software, customer information, or other data or materials that relate in any way to the Confidential   Information, whether paper or electronic and whether produced by Employee or obtained by a   member of the Company Group.  The covenants of this Section 9(a) shall apply to all Confidential   Information, whether now known or later to become known to Employee during the period that   Employee is employed by or affiliated with the Company or any other member of the Company   Group.                (b)   Notwithstanding any provision of Section 9(a) to the contrary, Employee   may make the following disclosures and uses of Confidential Information:                    (i)     disclosures to other employees of a member of the Company Group         who have a need to know the information in connection with the businesses of the         Company Group;                   (ii)     disclosures to customers and suppliers when, in the reasonable and         good faith belief of Employee, such disclosure is in connection with Employee’s                                          9 

 

       performance of Employee’s duties under this Agreement and is in the best interests of the        Company Group;                  (iii)    disclosures and uses that are approved in writing by the Board; or                   (iv)    disclosures to a person or entity that has: (x) been retained by a        member of  the Company Group to provide services to one or more members of the         Company Group; and (y) agreed in writing to abide by the terms of a confidentiality         agreement.                (c)   Upon the expiration of the Employment Period, and at any other time upon   request of the Company, Employee shall promptly surrender and deliver to the Company all   documents (including electronically stored information) and all copies thereof and all other   materials of any nature containing or pertaining to all Confidential Information and any other   property of any member of the Company Group (including any computer, mobile device or other   equipment issued by a member of the Company Group) in Employee’s possession, custody or   control and Employee shall not retain any such documents or other materials or property of any   member of the Company Group.  Within five (5) days of any such request, Employee shall certify  to the Company in writing that all such documents, materials and property have been returned to   the Company.                (d)   “Confidential Information” means all confidential, competitively   valuable, non-public or proprietary information, designs, ideas, concepts, improvements, product   developments, discoveries and inventions, whether patentable or not, that are or have been   conceived, made, developed or acquired by or disclosed to Employee (whether conveyed orally or   in writing), individually or in conjunction with others, during the period that Employee is or has   been employed by or affiliated with the Company or any other member of the Company Group   (whether during business hours or otherwise and whether on the Company’s premises or   otherwise) including: (i) technical information of any member of the Company Group, its affiliates,   its customers or other third parties, including computer programs, software, databases, data, ideas,   know-how, formulae, compositions, processes, discoveries, machines, inventions (whether   patentable or not), designs, developmental or experimental work, techniques, improvements, work   in process, research or test results, original works of authorship, training programs and procedures,   diagrams, charts, business and product development plans, and similar items; (ii) information   relating to any member of the Company Group’s businesses or properties, products or services   (including all such information relating to corporate opportunities, operations, future plans,   methods of doing business, business plans, strategies for developing business and market share,   research, financial and sales data, pricing terms, evaluations, opinions, interpretations, acquisition   prospects, the identity of customers or acquisition targets or their requirements, the identity of key  contacts within customers’ organizations or within the organization of acquisition prospects, or  marketing and merchandising techniques, prospective names and marks); and (iii) other valuable,  confidential information and trade secrets of any member of the Company Group, its affiliates, its   customers or other third parties;.  Moreover, all documents, videotapes, written presentations,   brochures, drawings, memoranda, notes, records, files, correspondence, manuals, models,   specifications, computer programs, e-mail, voice mail, electronic databases, maps, drawings,   architectural renditions, models and all other writings or materials of any type including or   embodying any of such information, ideas, concepts, improvements, discoveries, inventions and                                          10 

 

 other similar forms of expression are and shall be the sole and exclusive property of the Company   or the other applicable member of the Company Group and be subject to the same restrictions on   disclosure applicable to all Confidential Information pursuant to this Agreement.  For purposes of   this Agreement, Confidential Information shall not include any information that (i) is or becomes   generally available to the public other than as a result of a disclosure or wrongful act of Employee   or any of Employee’s agents; (ii) was available to Employee on a non-confidential basis before its   disclosure to Employee by a member of the Company Group; or (iii) becomes available to   Employee on a non-confidential basis from a source other than a member of the Company Group;   provided, however, that such source is not bound by a confidentiality agreement with, or other  obligation with respect to confidentiality to, a member of the Company Group.                 (e)   Notwithstanding the foregoing, nothing in this Agreement shall prohibit or  restrict Employee from lawfully: (i) initiating communications directly with, cooperating with,   providing information to, causing information to be provided to, or otherwise assisting in an   investigation by, any governmental authority (including the U.S. Securities and Exchange   Commission) regarding a possible violation of any law; (ii) responding to any inquiry or legal  process directed to Employee from any such governmental authority; (iii) testifying, participating  or otherwise assisting in any action or proceeding by any such governmental authority relating to   a possible violation of law; (iv) making disclosures required, or reasonably necessary, to comply   with applicable law; (v) making disclosures in legal or arbitral proceedings that are required or   reasonably necessary to enforce this Agreement; or (vi) making any other disclosures that are   protected under the whistleblower provisions of any applicable law.  Additionally, pursuant to the   federal Defend Trade Secrets Act of 2016, an individual shall not be held criminally or civilly   liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is   made (1) in confidence to a federal, state or local government official, either directly or indirectly,   or to an attorney and (2) solely for the purpose of reporting or investigating a suspected violation   of law; (B) is made to the individual’s attorney in relation to a lawsuit for retaliation against the   individual for reporting a suspected violation of law; or (C) is made in a complaint or other   document filed in a lawsuit or proceeding, if such filing is made under seal.  Nothing in this   Agreement requires Employee to obtain prior authorization before engaging in any conduct   described in this paragraph, or to notify the Company that Employee has engaged in any such   conduct.           10.   Non-Competition; Non-Solicitation; Non-Disparagement.                (a)   The Company shall provide Employee access to Confidential Information   for use only during the Employment Period, and Employee acknowledges and agrees that the   members of the Company Group will be entrusting Employee, in Employee’s unique and special   capacity, with developing the goodwill of the members of the Company Group, and in  consideration of the Company providing Employee with access to Confidential Information and   as an express incentive for the Company to enter into this Agreement and employ Employee   hereunder, Employee has voluntarily agreed to the covenants set forth in this Section 10.    Employee agrees and acknowledges that the limitations and restrictions set forth herein, including   geographical and temporal restrictions on certain competitive activities, are reasonable in all   respects, do not interfere with public interests, will not cause Employee undue hardship, and are   material and substantial parts of this Agreement intended and necessary to prevent unfair                                           11 

 

 competition and to protect the Confidential Information, goodwill and legitimate business interests   of each member of the Company Group.               (b)   During the Prohibited Period, Employee shall not, directly or indirectly, for  Employee or on behalf of or in conjunction with any other person or entity of any nature:                    (i)    engage in, participate in or take preparatory steps that result in        engagement or participation in the Business within the Market Area, including by directly        or indirectly: (A) owning, investing in, managing, controlling, participating in, consulting        with, contributing to, lending one’s name to, providing assistance to, operating, or being        an officer or director of, any person or entity engaged in or preparing to engage in the        Business, or (B) joining, becoming an employee or consultant of, or otherwise being        affiliated with, or rendering services for, any person or entity engaged in, or that has taken        preparatory steps that result in engagement in, the Business  (with respect to this clause        (B)) in which Employee’s duties or responsibilities are the same as or similar to the duties        or responsibilities that Employee had on behalf of any member of the Company Group or        in any manner that requires Employee to learn of or use nonpublic, confidential, proprietary        or trade secret information that is similar to the type of Confidential Information of which        Employee learned or used at any member of the Company Group or in any manner that        requires Employee to have client contacts or develop client relationships similar to the        client contacts or the development of client relationships in which Employee engaged at        any member of the Company Group;                   (ii)    appropriate any Business Opportunity of, or relating to, any member        of the Company Group located in the Market Area;                  (iii)    solicit, canvass, approach, encourage, entice or induce any customer        or supplier of any member of the Company Group which or with whom Employee had        contact, was involved as part of Employee’s job responsibilities (including oversight        responsibility) with any member of the Company Group and/or about whom Employee        learned Confidential Information to cease or lessen such customer’s or supplier’s business        with any member of the Company Group or otherwise adversely interference with the        relationship between any member of the Company Group and such customer or supplier;                   (iv)    hire or engage any employee or contractor of any member of the        Company Group with whom Employee had contact or solicit, canvass, approach,        encourage, entice or induce any such employee or contractor to terminate or reduce his,        her or its employment or engagement with any member of the Company Group; or                   (v)     attempt to do any of the foregoing.               (c)   Because of the difficulty of measuring economic losses to the members of  the Company Group as a result of a breach or threatened breach of the covenants set forth in  Section 9 and in this Section 10, and because of the immediate and irreparable damage that would   be caused to the members of the Company Group for which they would have no other adequate   remedy, the Company and each other member of the Company Group shall be entitled to enforce   the foregoing covenants, in the event of a breach or threatened breach, by injunctions and                                           12 

 

restraining orders from any court of competent jurisdiction, without the necessity of showing any  actual damages or that money damages would not afford an adequate remedy, and without the  necessity of posting any bond or other security.  The aforementioned equitable relief shall not be  the Company’s or any other member of the Company Group’s exclusive remedy for a breach but  instead shall be in addition to all other rights and remedies available to the Company and each  other member of the Company Group at law and equity.              (d)   The covenants in this Section 10, and each provision and portion hereof, are  severable and separate, and the unenforceability of any specific covenant (or portion thereof) shall  not affect the provisions of any other covenant (or portion thereof).  Moreover, in the event any  arbitrator or court of competent jurisdiction shall determine that the scope, time or territorial  restrictions set forth are unreasonable, then it is the intention of the parties that such restrictions be  enforced to the fullest extent which such arbitrator or court deems reasonable, and this Agreement  shall thereby be reformed to make the restrictive covenants contained herein enforceable to  maximum extent permitted by applicable law.               (e)   The following terms shall have the following meanings:                   (i)     “Business” shall mean the business and operations that are the same        or similar to those performed by the Company and any other member of the Company        Group during the Employment Period, or which any member of the Company Group had        material plans to engage in during the Employment Period, which business and operations        include (A) the development, manufacture, and delivery of prescriptive chemistry-based        technology and related services, including specialty and commodity chemicals to clients in        the energy (e.g. oil and gas), industrial cleaning, and agricultural industries around the        world, and (B) the business of developing and selling oil and gas analyzers and        measurement tools and related software and providing data analytics and data services in        the oil and gas industry.                  (ii)     “Business Opportunity” shall mean any commercial, investment or        other business opportunity relating to the Business.                   (iii)    “Market Area” shall mean the geographic area within (A) the state        of Texas and (B) a one hundred (100)-mile radius of any other oil and gas fields, basins,       shales, plays and geographic areas with respect to which the Company or any other member       of the Company Group conducts material business or has specific plans to conduct material       business during the Employment Period.                  (iv)     “Prohibited Period” shall mean the period during which Employee        is employed by any member of the Company Group and continuing for a period of six (6)        months following the date that Employee is no longer employed by any member of the        Company Group for any reason.               (f)   Subject to Section 9(e) above, Employee agrees that during the period from  and after the Effective Date, Employee will not, and will not cause or encourage any other person  or entity to, make, publish, or communicate, in any medium whatsoever, any disparaging, negative  or defamatory comments regarding any member of the Company Group or any of their respective                                         13 

 

 current or former directors, officers, members, managers, employees, partners, executives, direct   or indirect owners (including equityholders), investors, businesses, products or services.          11.   Ownership of Intellectual Property.                  (a)   Employee agrees that the Company shall own, and Employee shall (and   hereby does) assign, all right, title and interest (including patent rights, copyrights, trade secret   rights, mask work rights, trademark rights, and all other intellectual and industrial property rights   of any sort throughout the world) relating to any and all inventions (whether or not patentable),   discoveries, developments, improvements, innovations, works of authorship, mask works, designs,   know-how, ideas, formulae, processes, techniques, data and information authored, created,  contributed to, made or conceived or reduced to practice, in whole or in part, by Employee during  the period in which Employee is or has been employed by or affiliated with the Company or any  other member of the Company Group, whether or not registerable under U.S. law or the laws of  other jurisdictions, that either (a) relate, at the time of conception, reduction to practice, creation,  derivation or development, to any member of the Company Group’s businesses or actual or  anticipated research or development, or (b) were developed on any amount of the Company’s or  any other member of the Company Group’s time or with the use of any member of the Company  Group’s equipment, supplies, facilities or Confidential Information (all of the foregoing  collectively referred to herein as “Company Intellectual Property”), and Employee shall   promptly disclose all Company Intellectual Property to the Company in writing.  To support   Employee’s disclosure obligation herein, Employee shall keep and maintain adequate and current   written records of all Company Intellectual Property made by Employee (solely or jointly with   others) during the period in which Employee is or has been employed by or affiliated with the   Company or any other member of the Company Group in such form as may be specified from time   to time by the Company.  These records shall be available to, and remain the sole property of, the   Company at all times.                (b)   All of Employee’s works of authorship and associated copyrights created   during the Employment Period and in the scope of Employee’s employment or engagement shall   be deemed to be “works made for hire” within the meaning of the Copyright Act.  To the extent   any right, title and interest in and to Company Intellectual Property cannot be assigned by   Employee to the Company, Employee shall grant, and does hereby grant, to each member of the   Company Group an exclusive, perpetual, royalty-free, transferable, irrevocable, worldwide license   (with rights to sublicense through multiple tiers of sublicensees) to make, have made, use, sell,   offer for sale, import, export, reproduce, practice and otherwise commercialize such rights, title   and interest.                  (c)   Employee recognizes that this Agreement will not be deemed to require   assignment of any invention or intellectual property that Employee developed entirely on   Employee’s own time without using the equipment, supplies, facilities, trade secrets, or   Confidential Information of any member of the Company Group.  In addition, this Agreement does   not apply to any invention that qualifies fully for protection from assignment to the Company   under any specifically applicable state law or regulation.                (d)   To the extent allowed by law, this Section applies to all rights that may be   known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like, including                                          14 

 

 those rights set forth in 17 U.S.C. §106A (collectively, “Moral Rights”).  To the extent Employee   retain any Moral Rights under applicable law, Employee hereby ratifies and consents to any action   that may be taken with respect to such Moral Rights by or authorized by the Company or any   member of the Company Group, and Employee hereby waives and agrees not to assert any Moral   Rights with respect to such Moral Rights.  Employee shall confirm any such ratifications, consents,   waivers, and agreements from time to time as requested by the Company.                (e)   Employee hereby represents and warrants that there are no Prior Inventions,   and Employee shall make no claim of any rights to any Prior Inventions.  If, in the course of   Employee’s employment with or affiliation with the Company or any other member of the   Company Group, Employee incorporates into the product, process, or device of any member of   the Company Group a Prior Invention, each member of the Company Group is hereby granted and   will have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have   made, modify, use, import, export, offer for sale, sell and otherwise commercialize such Prior   Invention as part of or in connection with such product, process, or device of any member of the   Company Group.  “Prior Inventions” shall mean all inventions (whether or not patentable),   original works of authorship, designs, know-how, mask works, ideas, information, developments,   improvements, and trade secrets of which Employee is the sole or joint author, creator, contributor,   or inventor that were made or developed by Employee prior to Employee’s employment with or   affiliation with the Company or any other member of the Company Group, or in which Employee   asserts any intellectual property right, and which are applicable to or relate in any way to the   business, products, services, or demonstrably anticipated research and development or business of   any member of the Company Group.                (f)   Employee shall perform, during and after the period in which Employee is   or has been employed by or affiliated with the Company or any other member of the Company   Group, all acts deemed necessary or desirable by the Company to permit and assist each member   of the Company Group, at the Company’s expense, in obtaining and enforcing the full benefits,   enjoyment, rights and title throughout the world in the Company Intellectual Property and   Confidential Information assigned, to be assigned, or licensed to the Company under this   Agreement.  Such acts may include execution of documents and assistance or cooperation (i) in   the filing, prosecution, registration, and memorialization of assignment of any applicable patents,   copyrights, mask work, or other applications, (ii) in the enforcement of any applicable patents,   copyrights, mask work, moral rights, trade secrets, or other proprietary rights, and (iii) in other   legal proceedings related to the Company Intellectual Property or Confidential Information.                (g)   In the event that the Company (or, as applicable, a member of the Company   Group) is unable for any reason to secure Employee’s signature to any document required to file,   prosecute, register, or memorialize the assignment of any patent, copyright, mask work or other   applications or to enforce any patent, copyright, mask work, moral right, trade secret or other   proprietary right under any Confidential Information or Company Intellectual Property (including   derivative works, improvements, renewals, extensions, continuations, divisionals, continuations in   part, continuing patent applications, reissues, and reexaminations of such Company Intellectual   Property), Employee hereby irrevocably designates and appoints the Company and each of the   Company’s duly authorized officers and agents as Employee’s agents and attorneys-in-fact to act  for and on Employee’s behalf and instead of Employee, (i) to execute, file, prosecute, register and  memorialize the assignment of any such application, (ii) to execute and file any documentation                                          15 

 

 required for such enforcement, and (iii) to do all other lawfully permitted acts to further the filing,   prosecution, registration, memorialization of assignment, issuance, and enforcement of patents,   copyrights, mask works, moral rights, trade secrets or other rights under the Confidential   Information or Company Intellectual Property, all with the same legal force and effect as if   executed by Employee.                (h)   In the event that Employee enters into, on behalf of any member of the   Company Group, any contracts or agreements relating to any Confidential Information or   Company Intellectual Property, Employee shall assign such contracts or agreements to the   Company (or the applicable member of the Company Group) promptly, and in any event, prior to   Employee’s termination.  If the Company (or the applicable member of the Company Group) is   unable for any reason to secure Employee’s signature to any document required to assign said   contracts or agreements, or if Employee does not assign said contracts or agreements to the   Company (or the applicable member of the Company Group) prior to Employee’s termination,   Employee hereby irrevocably designates and appoints the Company (or the applicable member of   the Company Group) and each of the Company’s duly authorized officers and agents as   Employee’s agents and attorneys-in-fact to act for and on Employee’s behalf and instead of    Employee to execute said assignments and to do all other lawfully permitted acts to further the   execution of said documents.          12.   Arbitration.                (a)   Subject to Section 12(b), any dispute, controversy or claim between   Employee and the Company or any other member of the Company Group arising out of or relating  to Employee’s duties to the Company, this Agreement, or Employee’s employment or engagement   with any member of the Company Group will be finally adjudicated by confidential arbitration in  Houston, Texas, in accordance with the then-existing American Arbitration Association (“AAA”)   Employment Arbitration Rules.  The arbitrator’s decision and arbitration award shall be final and   binding on both parties.  Any arbitration conducted under this Section 12 shall be private, and shall   be heard by a single arbitrator (the “Arbitrator”) selected in accordance with the then-applicable   rules of the AAA.  The Arbitrator shall expeditiously hear and decide all matters concerning the   dispute.  Except as expressly provided to the contrary in this Agreement, the Arbitrator shall have   the power to (i) gather such materials, information, testimony and evidence as the Arbitrator deems   relevant to the dispute before him or her (and each party will provide such materials, information,   testimony and evidence requested by the Arbitrator), and (ii) grant injunctive relief and enforce   specific performance.  All disputes shall be arbitrated on an individual basis, and each party hereto   hereby foregoes and waives any right to arbitrate any dispute as a class action or collective action   or on a consolidated basis or in a representative capacity on behalf of other persons or entities who   are claimed to be similarly situated, or to participate as a class member in such a proceeding.  The   decision of the Arbitrator shall be reasoned, rendered in writing, be final and binding upon the   disputing parties and the parties agree that judgment upon the award may be entered by any court   of competent jurisdiction.  The arbitrator will be empowered to award either party any remedy at  law or in equity that the party would otherwise have been entitled to had the matter been litigated  in court, including, but not limited to, general, special and punitive damages, injunctive relief,  costs and attorney fees; provided, however, that the authority to award any remedy is subject to   whatever limitations, if any, exist in the applicable law on such remedies.  The party whom the   Arbitrator determines is the prevailing party in such arbitration shall receive, in addition to any                                          16 

 

 other award pursuant to such arbitration or associated judgment, reimbursement from the other   party of all reasonable legal fees and costs associated with such arbitration and associated   judgment.                (b)   Notwithstanding Section 12(a), either party may make a timely application   for, and obtain, judicial emergency or temporary injunctive relief to enforce any of the provisions   of Sections 9 through 11; provided, however, that the remainder of any such dispute (beyond the   application for emergency or temporary injunctive relief) shall be subject to arbitration under this   Section 12.                (c)   By entering into this Agreement and entering into the arbitration provisions   of this Section 12, THE PARTIES EXPRESSLY ACKNOWLEDGE AND AGREE THAT THEY   ARE KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVING THEIR RIGHTS   TO A JURY TRIAL.                (d)   Nothing in this Section 12 shall prohibit a party to this Agreement from   (i) instituting litigation to enforce any arbitration award, or (ii) joining the other party to this   Agreement in a litigation initiated by a person or entity that is not a party to this Agreement.    Further, nothing in this Section 12 precludes Employee from filing a charge or complaint with a   federal, state or local governmental, administrative or regulatory agency or shall require arbitration  of any disputes which, by law, cannot be the subject of a compulsory arbitration agreement.          13.   Defense of Claims.  During the Employment Period and thereafter, upon request   from the Company, Employee shall cooperate with any member of the Company Group in the  defense of any claims or actions that may be made by or against any member of the Company  Group that relate to Employee’s actual or prior areas of responsibility.          14.   Withholdings; Deductions.  The Company may withhold and deduct from any   benefits and payments made or to be made pursuant to this Agreement (a) all federal, state, local   and other taxes as may be required pursuant to any law or governmental regulation or ruling and   (b) any deductions consented to in writing by Employee.          15.   Title and Headings; Construction.  Titles and headings to Sections hereof are for   the purpose of reference only and shall in no way limit, define or otherwise affect the provisions   hereof.  Any and all Exhibits or Attachments referred to in this Agreement are, by such reference,   incorporated herein and made a part hereof for all purposes.  Unless the context requires otherwise,   all references to laws, regulations, contracts, documents, agreements and instruments refer to such   laws, regulations, contracts, documents, agreements and instruments as they may be amended,  restated or otherwise modified from time to time, and references to particular provisions of laws  or regulations include a reference to the corresponding provisions of any succeeding law or  regulation.  All references to “dollars” or “$” in this Agreement refer to United States dollars.  The  words “herein”, “hereof”, “hereunder” and other compounds of the word “here” shall refer to the  entire Agreement, including all Exhibits attached hereto, and not to any particular provision hereof.    The word “or” is not exclusive.  Wherever the context so requires, the masculine gender includes   the feminine or neuter, and the singular number includes the plural and conversely.  All references   to “including” shall be construed as meaning “including without limitation.”  Neither this   Agreement nor any uncertainty or ambiguity herein shall be construed or resolved against any                                          17 

 

 party hereto, whether under any rule of construction or otherwise.  On the contrary, this Agreement   has been reviewed by each of the parties hereto and shall be construed and interpreted according   to the ordinary meaning of the words used so as to fairly accomplish the purposes and intentions   of the parties hereto.          16.   Applicable Law; Submission to Jurisdiction.  This Agreement shall in all   respects be construed exclusively according to the laws of the State of Texas without regard to its  conflict of laws principles that would result in the application of the laws of another jurisdiction.   With respect to any claim or dispute related to or arising under this Agreement, the parties hereby  consent to the arbitration provisions of Section 12 and recognize and agree that should any resort   to a court be necessary and permitted under this Agreement, then they consent to the exclusive   jurisdiction, forum and venue of the state and federal courts (as applicable) located in Houston,   Texas.          17.   Entire Agreement and Amendment.    This Agreement contains the entire   agreement of the parties with respect to the matters covered herein and supersedes all prior and   contemporaneous agreements and understandings, oral or written, between the parties hereto   concerning the subject matter hereof; provided, however, that the provisions of this Agreement are   in addition to and complement (and do not replace or supersede) any other written agreement(s)   or parts thereof between Employee and any member of the Company Group that create restrictions   on Employee with respect to confidentiality, non-disclosure, non-competition, non-solicitation,   no-hire, non-interference or non-disparagement, including that certain Membership Interests   Purchase Agreement between the Company, JP3, and the other parties thereto, dated as of the   Effective Date.  Without limiting the scope of the preceding sentence, except as otherwise   expressly provided in this Section 17, all understandings and agreements preceding the Effective   Date and relating to the subject matter hereof (including that certain Employment Agreement   between JP3 Measurement, LLC and Employee, effective as of May 1, 2013 (the “Prior   Agreement”)) are hereby null and void and of no further force or effect, and this Agreement shall   supersede all other agreements, written or oral, that purport to govern the terms of Employee’s   employment (including Employee’s compensation) with any member of the Company Group.    Employee acknowledges and agrees that the Prior Agreement is hereby terminated and has been   satisfied in full, as has any other employment agreement between Employee and any member of   the Company Group, provided, however, that the termination of the Prior Agreement shall not be   deemed to waive any accrued rights or obligations of the parties thereto, including any obligation   to make a payment to Employee in connection with any change in control of JP3 that occurred on   or before the Effective Date.  In entering into this Agreement, Employee expressly acknowledges   and agrees that Employee has received all sums and compensation that Employee has been owed,   is owed or ever could be owed pursuant to the agreement(s) referenced in the previous sentence   and for services provided to any member of the Company Group through the date that Employee   signs this Agreement, with the exception of any unpaid base salary for the pay period that includes  the date on which Employee signs this Agreement.  This Agreement may be amended only by a  written instrument executed by both parties hereto.          18.   Waiver of Breach.  Any waiver of this Agreement must be in writing and executed   by the party to be bound by such waiver.  No waiver by either party hereto of a breach of any   provision of this Agreement by the other party, or of compliance with any condition or provision   of this Agreement to be performed by such other party, will operate or be construed as a waiver of                                          18 

 

 any subsequent breach by such other party or any similar or dissimilar provision or condition at  the same or any subsequent time.  The failure of either party hereto to take any action by reason  of any breach will not deprive such party of the right to take action at any time.          19.   Assignment.  This Agreement is personal to Employee, and neither this Agreement   nor any rights or obligations hereunder shall be assignable or otherwise transferred by Employee.    The Company may assign this Agreement without Employee’s consent, including to any member  of the Company Group and to any successor to or acquirer of (whether by merger, purchase or  otherwise) the equity, assets or businesses of the Company.          20.   Notices.  Notices provided for in this Agreement shall be in writing and shall be   deemed to have been duly received (a) when delivered in person, (b) when sent by electronic mail   transmission (with confirmation of receipt) on a business day to the e-mail address set forth below,  if applicable, (c) on the first business day after such notice is sent by express overnight courier  service, or (d) on the second business day following deposit with an internationally-recognized  second-day courier service with proof of receipt maintained, in each case, to the following address,  as applicable, or such other address or to the attention of such other person as the recipient party  shall have specified by prior written notice to the sending party:          If to the Company, addressed to:                      Flotek Industries, Inc.                     Attn: General Counsel                     10603 W. Sam Houston Pkwy. N., Suite 300                     Houston, Texas 77043          If to Employee, addressed to: Employee’s most recent address and personal email         address in the records of the Company.          21.   Counterparts.  This Agreement may be executed in any number of counterparts,   including by electronic mail or facsimile, each of which when so executed and delivered shall be   an original, but all such counterparts shall together constitute one and the same instrument.  Each   counterpart may consist of a copy hereof containing multiple signature pages, each signed by one   party, but together signed by both parties hereto.          22.   Deemed Resignations.  Except as otherwise determined by the Board or as   otherwise agreed to in writing by Employee and any member of the Company Group prior to the   termination of Employee’s employment with the Company or any member of the Company Group,   any termination of Employee’s employment shall constitute, as applicable, an automatic   resignation of Employee: (a) as an officer of the Company and each member of the Company   Group; (b) from the Board; and (c) from the board of directors or board of managers (or similar   governing body) of any member of the Company Group and from the board of directors or board   of managers (or similar governing body) of any corporation, limited liability entity, unlimited   liability entity or other entity in which any member of the Company Group holds an equity interest   and with respect to which board of directors or board of managers (or similar governing body)   Employee serves as such Company Group member’s designee or other representative.           23.   Section 409A.                                            19 

 

             (a)   Notwithstanding any provision of this Agreement to the contrary, all   provisions of this Agreement are intended to comply with Section 409A of the Internal Revenue   Code of 1986 (the “Code”), and the applicable Treasury regulations and administrative guidance   issued thereunder (collectively, “Section 409A”) or an exemption therefrom and shall be construed   and administered in accordance with such intent.  Any payments under this Agreement that may   be excluded from Section 409A either as separation pay due to an involuntary separation from   service or as a short-term deferral shall be excluded from Section 409A to the maximum extent   possible.  For purposes of Section 409A, each installment payment provided under this Agreement   shall be treated as a separate payment.  Any payments to be made under this Agreement upon a   termination of Employee’s employment shall only be made if such termination of employment   constitutes a “separation from service” under Section 409A.                  (b)   To the extent that any right to reimbursement of expenses or payment of   any benefit in-kind under this Agreement constitutes nonqualified deferred compensation (within   the meaning of Section 409A), (i) any such expense reimbursement shall be made by the Company   no later than the last day of Employee’s taxable year following the taxable year in which such   expense was incurred by Employee, (ii) the right to reimbursement or in-kind benefits shall not be  subject to liquidation or exchange for another benefit, and (iii) the amount of expenses eligible for  reimbursement or in-kind benefits provided during any taxable year shall not affect the expenses  eligible for reimbursement or in-kind benefits to be provided in any other taxable year; provided,  that the foregoing clause shall not be violated with regard to expenses reimbursed under any  arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a  limit related to the period in which the arrangement is in effect.                  (c)   Notwithstanding any provision in this Agreement to the contrary, if any   payment or benefit provided for herein would be subject to additional taxes and interest under   Section 409A if Employee’s receipt of such payment or benefit is not delayed until the earlier of   (i) the date of Employee’s death and (ii) the date that is six (6) months after the Termination Date   (such date, the “Section 409A Payment Date”), then such payment or benefit shall not be provided   to Employee (or Employee’s estate, if applicable) until the Section 409A Payment Date.                (d)   To the extent that the aggregate amount of the Salary Continuation   installments that would otherwise be paid pursuant to the provisions of Section 7(f)(i) after March   15 of the calendar year following the calendar year in which the Termination Date occurs (the   “Applicable March 15”) exceeds the maximum exemption amount under Treasury Regulation   Section 1.409A-1(b)(9)(iii)(A), then such excess shall be paid to Employee in a lump sum on the   Applicable March 15 (or the first business day preceding the Applicable March 15 if the   Applicable March 15 is not a business day) and the Severance Benefits payable after the   Applicable March 15 shall be reduced by such excess (beginning with the installment first payable   after the Applicable March 15 and continuing with the next succeeding installment until the   aggregate reduction equals such excess).                (e)   Notwithstanding the foregoing, the Company makes no representations that   the payments and benefits provided under this Agreement are exempt from, or compliant with,   Section 409A and in no event shall any member of the Company Group be liable for all or any   portion of any taxes, penalties, interest or other expenses that may be incurred by Employee on   account of non-compliance with Section 409A.                                          20 

 

       24.   Clawback.  To the extent required by applicable law or any applicable securities   exchange listing standards, or as otherwise determined by the Board (or a committee thereof),   amounts paid or payable under this Agreement shall be subject to the provisions of any applicable   clawback policies or procedures adopted by any member of the Company Group, which clawback  policies or procedures may provide for forfeiture and/or recoupment of amounts paid or payable  under this Agreement.  Notwithstanding any provision of this Agreement to the contrary, each  member of the Company Group reserves the right, without the consent of Employee, to adopt any  such clawback policies and procedures, including such policies and procedures applicable to this  Agreement with retroactive effect.          25.   Effect of Termination.  The provisions of Sections 7, 9, 10, 11, 12, 13, 14 and 22   and those provisions necessary to interpret and enforce them, shall survive any termination of this   Agreement and any termination of the employment relationship between Employee and the   Company.          26.   Third-Party Beneficiaries.  Each member of the Company Group that is not a   signatory to this Agreement shall be a third-party beneficiary of Employee’s obligations under   Sections 8, 9, 10, 11, 12, 16 and 22 and shall be entitled to enforce such obligations as if a party   hereto.          27.   Severability.  If an arbitrator or court of competent jurisdiction determines that any   provision of this Agreement (or portion thereof) is invalid or unenforceable, then the invalidity or   unenforceability of that provision (or portion thereof) shall not affect the validity or enforceability   of any other provision of this Agreement, and all other provisions shall remain in full force and   effect.                          [Remainder of Page Intentionally Blank;                                Signature Page Follows]                                          21 

 

                                                                                       IN WITNESS WHEREOF, Employee and the Company each have caused this Agreement  to be executed and effective as of the Effective Date.                                          FLOTEK INDUSTRIES, INC.                                        By: /s/John W. Gibson, Jr___________________                  Name:   John W. Gibson, Jr.                  Title: President, Chief Executive Officer and Chairman of the Board                                                            EMPLOYEE                                          /s/Matthew R. Thomas_______________________              Matthew R. Thomas                          SIGNATURE PAGE TO EMPLOYMENT AGREEMENTExhibit 4.10

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

NUTRIBAND
INC.

 

	Warrant
Shares: 25,000	Issuance
           Date: October 30, 2019

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, PLATINUM POINT CAPITAL
LLC, a Nevada limited liability company, or its registered assigns (the “Holder”), with an address at: 211 East
43rd Street., Suite 626, New York, NY 10017, or its assigns (the “Holder”) is entitled, upon the terms and subject
to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial
Exercise Date”) and on or prior to the close of business on the third anniversary of the Issuance Date (the “Termination
Date”) but not thereafter, to subscribe for and purchase from NUTRIBAND INC., a Nevada corporation, with headquarters
located at 121 South Orange Ave., Suite 1500, Orlando, Florida 32801 (the “Company”), up to 25,000 shares (as
subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of
Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the “Purchase Agreement”), dated October 29, 2019, among the Company and the
purchasers signatory thereto and the note issued to the initial Holder contemporaneously with this Warrant (the “Note”).

 

    1

     

    

 

Section
2. Exercise.

 

a) Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the
Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the
Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on
the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Within two (2)
Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
Notwithstanding anything herein to the contrary (although the Holder may surrender the Warrant to, and receive a replacement
Warrant from, the Company), the Holder shall not be required to physically surrender this Warrant to the Company until the
Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final
Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise Form within one (1) Trading Day of delivery of such notice. The Holder and
any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.

 

b) Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be the lesser of (i) $20.90 or, (ii) if the
Company completes a public offering of its common stock, 110% of the initial public offering price of the Common Stock in the
next firm commitment public offering of the Company’s securities, subject to adjustment as described herein (“Exercise
Price”). When exercising this Warrant for cash, other than as a result of a Call Notice, the Holder may pay for fifty
percent (50%) of the Exercise Price for any warrants purchased pursuant to an Exercise Notice submitted in response to a Call
Notice by cancelling a portion of the debt owed on the Note equal to such amount.

 

c) Cashless
Exercise. In the event that there is no effective registration statement registering the Warrant Shares within six (6) months
from Issuance Date, then this Warrant may also be exercised at the Holder’s election, in whole or in part, at such time
by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal
to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A)	=	the
                                         VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise
                                         this Warrant by means of a “cashless exercise,” as set forth in the applicable
                                         Notice of Exercise;

 

	 	(B)	=
                                         	the
Exercise Price of this Warrant, as adjusted hereunder; and

 

	 	(X)	=
                                         	the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if
such exercise were by means of a cash exercise rather than a cashless exercise.

 

    2

     

    

 

Notwithstanding
anything herein to the contrary, on the Termination Date, unless the Holder notifies the Company otherwise, if there is no effective
registration statement registering the Warrant Shares, or no current prospectus available for, the resale of the Warrant Shares
by the Holder, then this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

 

		d)	Mechanics
                                         of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder’s prime broker with The Depository Trust Company through its
Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and
either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) this Warrant is being exercised via cashless exercise and Rule 144 is available, and otherwise by
physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days
after the latest of (A) the delivery to the Company of the Notice of Exercise, (B) surrender of this Warrant (if required) and
(C) payment of the aggregate Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the
“Warrant Share Delivery Date”). The Warrant Shares shall be deemed to have been issued, and Holder or any other
person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as
of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted)
and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having
been paid. The Company understands that a delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could
result in economic loss to the Holder. As compensation to the Holder for such loss, the Company agrees to pay (as liquidated damages
and not as a penalty) to the Holder for late issuance of Warrant Shares upon exercise of this Warrant the proportionate amount
of $10 per Trading Day (increasing to $20 per Trading Day after the fifth (5th) Trading Day) after the Warrant Share
Delivery Date for each $1,000 of Exercise Price of Warrant Shares for which this Warrant is exercised which are not timely delivered.
The Company shall pay any payments incurred under this Section in immediately available funds upon demand. Furthermore, in addition
to any other remedies which may be available to the Holder, in the event that the Company fails for any reason to effect delivery
of the Warrant Shares by the Warrant Share Delivery Date, the Holder may revoke all or part of the relevant Warrant exercise by
delivery of a notice to such effect to the Company, whereupon the Company and the Holder shall each be restored to their respective
positions immediately prior to the exercise of the relevant portion of this Warrant, except that the liquidated damages described
above shall be payable through the date notice of revocation or rescission is given to the Company.

 

    3

     

    

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a
Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates
representing Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this
Warrant.

 

iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing
the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right, at any
time prior to issuance of such Warrant Shares, to rescind such exercise.

 

iv. Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing the
Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases,
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving
upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by
which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase
obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number
of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to
the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect
of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

v. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon
such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an
amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

vi. Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of
any Notice of Exercise.

 

vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

 

    4

     

    

 

e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares
of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion
of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder
that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of
Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by
the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of
Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm
orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
exercise of this Warrant. The Holder may decrease the Beneficial Ownership Limitation at any time and the Holder, upon not
less than 61 days’ prior notice to the Company, may increase the Beneficial Ownership Limitation provisions of this
Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase will not be
effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. In exercising or
converting this Warrant, the Holder shall represent that such exercise or conversion does not result in a violation of the
Beneficial Ownership Limitation.

 

f) Call
Provision. If, at any time after the Initial Exercise Date, (i) the VWAP of the Common Stock on the principal Trading Market
as reported by Bloomberg L.P. exceeds 140% of the Exercise Price in effect for ten (10) consecutive Trading Days (the “Measurement
Period”); (ii) the aggregate value of the shares of the Company’s common stock traded on its principal Trading
Market as reported by Bloomberg, L.P. during the previous five (5) trading Days exceeds two and a half (2.5) times the amount
of shares being cancelled by the relevant Call Notice,

 

    5

     

    

 

(iii) there
is an effective registration statement under the Securities Act of 1933, as amended covering the resale of the shares of
Common Stock issuable upon exercise of this Warrant, (iv) the Holder is not in possession of any information provided by the
Company that constitutes material nonpublic information, (v) the number of shares being called will not result in the Holder
exceeding the Beneficial Ownership Limitation, and (vi) an Event of Default (as defined in the Note) nor an event which with
the passage of time or the giving of notice could become an Event of Default is not pending, then the Company may call for
cancellation of that portion of this Warrant for which an Exercise Notice has not yet been delivered as of the date of the
Call Notice (as defined below). The Company shall deliver to the Holder a written notice (a “Call Notice”)
of any call for cancellation of the Warrants pursuant to this Section 2(f) within three (3) Trading Days following the last
day of the Measurement Period. In furtherance of the foregoing, the Company covenants and agrees that it will honor all
Exercise Notices that are tendered on or before 5:29 p.m. (local time in New York City, New York) on the Call Date. A Call
Notice may not be given to the Holder with respect to any Warrants which if exercised pursuant to Section 2(a) would cause
such Holder to exceed the Beneficial Ownership Limitation. A Call Notice may not be given later than sixty (60) days before
the Expiration Date, nor more often than one time each 10 Trading Days. Unless otherwise agreed to by the Holder of this
Warrant, a Call Notice must be given to all other holders of Warrants issued pursuant to the Purchase Agreement in proportion
to the amount of Warrants held by all such Holders on the date of the Call Notice without giving effect to the Beneficial
Ownership Limitation. When exercising this Warrant as a result of a Call Notice, the Holder may, at its election, pay for up
to fifty percent (50%) of the Exercise Price for any Warrant Shares purchased pursuant to an Exercise Notice submitted in
response to a Call Notice by cancelling a portion of the debt owed on the Note equal to such amount. In the event the during
the 10 Trading Days after the Holder exercises this Warrant pursuant to a Call Notice, the closing price of the
Company’s Common Stock on the Trading Market falls below the Exercise Price pursuant to which Warrant Shares were
acquired pursuant to such Call Notice for a period of three consecutive trading days (such lower price the “Reset
Price”), then the Company shall issue additional shares of Common Stock so that the per share purchase price of the
Warrant Shares purchased pursuant to such Call Notice shall equal the Reset Price.

 

Section
3. Certain Adjustments.

 

a) Adjustment
Upon Issuance of Shares of Common Stock. If and whenever on or after the date hereof, the Company issues or sells, or in accordance
with this Section 3 is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of
Common Stock owned or held by or for the account of the Company, but excluding any Exempt Issuance (as defined below) issued or
sold or deemed to have been issued or sold) for a consideration per share (the “New Issuance Price”) less than
a price equal to the Exercise Price in effect immediately prior to such issue or sale or deemed issuance or sale (such Exercise
Price then in effect is referred to as the “Applicable Price”) (the foregoing a “Dilutive Issuance”),
then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be reduced to the New Issuance Price. For
all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and consideration per share
under this Section 3(e)), the following shall be applicable:

 

i. Issuance
of Common Stock Equivalents. If the Company in any manner issues or sells any Common Stock Equivalents (other than Common
Stock Equivalents that qualify as Exempt Issuances) and the lowest price per share for which one share of Common Stock is
issuable upon the conversion, exercise or exchange thereof is less than the Applicable Price, then such share of Common Stock
shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale of such
Common Stock Equivalents for such price per share. For the purposes of this Section 3(e)(ii), the “lowest price per
share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof” shall be equal
to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with
respect to one share of Common Stock upon the issuance or sale of the Common Stock Equivalent and upon conversion, exercise
or exchange of such Common Stock Equivalent and (y) the lowest conversion price set forth in such Common Stock Equivalent for
which one share of Common Stock is issuable upon conversion, exercise or exchange thereof minus (2) the sum of all amounts
paid or payable to the holder of such Common Stock Equivalent (or any other Person) upon the issuance or sale of such Common
Stock Equivalent plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of
such Common Stock Equivalent (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price
shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common
Stock Equivalents, and if any such issue or sale of such Common Stock Equivalents is made upon exercise of any options for
which adjustment of this Warrant has been or is to be made pursuant to other provisions of this Section 3(e), except as
contemplated below, no further adjustment of the Exercise Price shall be made by reason of such issue or sale.

 

    6

     

    

 

ii. Change
in Option Price or Rate of Conversion. If the purchase or exercise price provided for in any options, the additional consideration,
if any, payable upon the issue, conversion, exercise or exchange of any Common Stock Equivalents, or the rate at which any Common
Stock Equivalents are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any
time, the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would
have been in effect at such time had such options or Common Stock Equivalents provided for such increased or decreased purchase
price, additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted,
issued or sold. For purposes of this Section 3, if the terms of any option or Common Stock Equivalent that was outstanding as
of the date of issuance of this Warrant are increased or decreased in the manner described in the immediately preceding sentence,
then such option or Common Stock Equivalent and the shares of Common Stock deemed issuable upon exercise, conversion or exchange
thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section
3 shall be made if such adjustment would result in an increase of the Exercise Price then in effect.

 

iii Calculation
of Consideration Received. The price at which any Convertible Security is issued shall be the amount received for the
issuance of the Convertible Security plus the minimum amount of additional consideration which is payable upon exercise or
conversion of the Convertible Security. If the Company issues securities as a unit, regardless of whether such issuance is
defined as a unit, a separate computation shall be made with respect to (x) shares of Common Stock and convertible securities
(based on the maximum number of shares of Common Stock which may be issued upon conversion, including conversion of interest
or dividends, but excluding warrants, rights and options) and (y) warrants, options or rights, with a separate computation
being made as to each warrant, option or right which is issued. If warrants, options or rights are issued, the Company shall
not be deemed to have received any consideration for the issuance of the shares upon exercise of the warrant, option or right
other than the lowest exercise price provided therein. If any shares of Common Stock, options or Common Stock Equivalents are
issued or sold for a consideration other than cash (for the purpose of determining the consideration paid for such Common
Stock, option or Common Stock Equivalent), the amount of such consideration received by the Company will be the fair value of
such consideration, except where such consideration consists of publicly traded securities, in which case the amount of
consideration received by the Company for such securities will be the arithmetic average of the VWAPs of such security for
each of the five (5) Trading Days immediately preceding the date of receipt. If any shares of Common Stock or Common Stock
Equivalents are issued with an Adjustment Right, the value of the Adjustment Right shall be computed in the manner that such
the right is reflected in the Company’s financial statements. An Adjustment Right shall mean a right to exercise the
convertible security based on the market price at the time of exercise or conversion.

 

    7

     

    

 

iv. Exempt
Issuances. shall mean (i) issuances of securities in a firm commitment underwritten public offering, (ii) issuances to
employees, officers, directors, contractors, consultants or other advisors pursuant to an equity incentive plan approved by
the Board, (iii) issuances to strategic partners or other parties in connection with a commercial relationship, or providing
the Company with equipment leases, real property leases or similar transactions approved by the Board (iv) issuances
of securities as consideration for a merger, consolidation or purchase of assets, or in connection with any strategic
partnership or joint venture (the primary purpose of which is not to raise equity or debt capital), or in connection with the
disposition or acquisition of a business, product or license by the Company; (v) the issuance of securities pursuant to the
Notes and Warrants that were issued pursuant to the Purchase Agreement; or (vi) an issuance approved by the Holder as an
Exempt Issuance. For the avoidance of doubt, a commercial relationship referred to in clause (iii) shall be for services
rendered accompanied by a valid invoice.

 

b)
Voluntary Reduction. The Company may unilaterally reduce the Exercise Price at any time.

 

c) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

 d) Notice to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to
the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up
of the affairs of the Company, then, in each case, to the extent that such information constitutes material non-public information
(as determined in good faith by the Company) the Company shall follow the procedure described in Section 13 of the Subscription
Agreement and shall deliver to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at
least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on
which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is
not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice
or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

e) Increase
in Warrant Shares. In the event the Exercise Price is reduced for any reason, including Section 3 of this Warrant, the number
of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price payable hereunder, after taking
into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment.

 

    8

     

    

 

f) Reclassification,
Reorganization or Merger. In case of any reclassification, capital reorganization or other change of outstanding shares
of Common Stock of the Company, or in case of any consolidation or merger of the Company with or into another corporation
(other than a merger in which the Company is the continuing corporation and which does not result in any reclassification,
capital reorganization or other change of outstanding shares of Common Stock of the class issuable upon exercise of this
Warrant), the Company shall, as a condition precedent to such transaction, cause effective provisions to be made so that the
Holder shall have the right thereafter by exercising this Warrant, to purchase the kind and amount of shares of stock and
other securities and property receivable upon such reclassification, capital reorganization and other change, consolidation
or merger by the Holder of the number of shares of Common Stock which might have been purchased upon exercise of this Warrant
immediately prior to such reclassification, change, consolidation or merger. Any such provision shall include provision for
adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Warrant. The
foregoing provisions of this Section (i)(1) shall similarly apply to successive reclassifications, capital reorganizations
and changes of shares of Common Stock and to successive consolidations, mergers, sales or conveyances.

 

Section
4. Transfer of Warrant.

 

a) Transferability.
Subject to compliance with any applicable securities laws and the provisions of the Purchase Agreement, this Warrant and all rights
hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, to an accredited investor,
as defined in Rule 501(a) of the SEC pursuant to the Securities Act, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.

 

b) New
Warrants. Subject to compliance with all applicable securities laws, this Warrant may be divided or combined with other Warrants
upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a),
as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant
or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued
on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except
as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
“Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

    9

     

    

 

Section
5. Miscellaneous.

 

a) No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which shall not include
the posting of a bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will
make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or
stock certificate.

 

c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.

 

d) Authorized
Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and
unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any
purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates
for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and non-assessable and free from all taxes, liens and charges created by the Company in respect of
the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant
is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof. To the extent that the Company shall
require an amendment to its articles of incorporation to increase its authorized Common Stock or reduce the par value of its Common
Stock, the Company’s obligation pursuant to this Section 5(d) shall be to hold a meeting of its stockholders to increase
the authorized Common Stock or reduce the par value to a number reasonably acceptable to the holders of a majority of the then
outstanding Warrants and to recommend stockholder approval of the amendment.

 

    10

     

    

 

e) Jurisdiction.
All questions concerning governing law, jurisdiction, venue and the construction, validity, enforcement and interpretation of
this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

 

f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, or unless exercised
in a cashless exercise when Rule 144 is available, and the Holder does not utilize cashless exercise, will have restrictions upon
resale imposed by state and federal securities laws.

 

g) Non-waiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.

 

h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.

 

i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be
entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be
adequate.

 

    11

     

    

 

k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.

 

l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holders
of not less than a majority of the outstanding Warrants issued pursuant to the Purchase Agreement.

 

m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

********************

 

(Signature
Page Follows)

  

    12

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	NUTRIBAND
    INC.
	 	 	 
	 	By:	/s/
    Gareth Sheridan
	 	Name: 	Gareth
    Sheridan
	 	Title:	Chief
    Executive Officer

 

    13

     

    

 

NOTICE
OF EXERCISE

 

TO: Nutriband
Inc.:

 

(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.

 

		(2)	Payment
                                         shall take the form of (check applicable box):

 

☐ 
in lawful money of the United States;

 

☐
[if permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c); or

 

☐
by cancelling $________ of the amount due on the Note issued by the

 

Company
to the undersigned.

 

(3) Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

 

_______________________________

 

(4) After
giving effect to this Notice of Exercise, the undersigned will not have exceeded the Beneficial Ownership Limitation.

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity:

 

________________________________________________________________

Signature
of Authorized Signatory of Investing Entity:

__________________________________________

 

Name
of Authorized Signatory:

 

___________________________________________________________

Title
of Authorized Signatory:

____________________________________________________________

Date:

__________________________________________________________________________

 

    14

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute 

this
form and supply required information.

Do
not use this form to exercise the warrant.)

 

NUTRIBAND
INC.

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby
assigned to

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

Dated:
______________, _______

 

Holder’s
Signature: _____________________________

 

Holder’s
Address: _____________________________

 

  _____________________________

 

Signature
Guaranteed: ___________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

 

 

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]